Ronquest NA, Paret K, Lucas A, Ciepielewska M, Hagan M. Quantifying the value of introducing an oral drug delivery option for edaravone: a review of analyses evaluating the economic impact of oral versus intravenous formulations. Clinicoecon Outcomes Res. 2022 Jul 27;14:499-511. doi: 10.2147/CEOR.S359025
Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097
Kim ES, Tkatch R, Martin D, MacLeod S, Sandy L, Yeh C. Resilient aging: psychological well-being and social well-being as targets for the promotion of healthy aging. Gerontol Geriatr Med. 2021 Mar 23;7:233372142. doi: 10.1177/23337214211002951
Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Clinicoecon Outcomes Res. 2020 Sep 14;2020(12):515-26. doi: 10.2147/CEOR.S262772
Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US budget impact model for selinexor in relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2020 Jun 19;12:317-25. doi: 10.2147/CEOR.S251070
Rajagopalan K, Candrilli SD, Ajmera M. Impact of antiepileptic drug-treatment burden on health-care-resource utilization and costs. Clinicoecon Outcomes Res. 2018 Oct 16;2018(10):619-27. doi: 10.2147/CEOR.S180913
Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017 Oct 16;9:641-52. doi: 10.2147/CEOR.S135609
Tkatch R, Musich S, MacLeod S, Alsgaard K, Hawkins K, Yeh CS. Population health management for older adults: review of interventions for promoting successful aging across the health continuum. Gerontol Geriatr Med. 2016 Sep 18;2:233372141. doi: 10.1177/2333721416667877
Mao N, Lesher B, Liu Q, Qin L, Chen Y, Gao X, Earnshaw SR, McDade CL, Claudie C. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. Clinicoecon Outcomes Res. 2016 Jun;8:275-85.
Musich S, MacLeod S, Bhattarai GR, Wang SS, Hawkins K, Bottone, Jr. FG, Yeh CS. The impact of obesity on health utilization and expenditures in a medicare supplement. Gerontol Geriatr Med. 2016 Jan 19;2:233372141. doi: 10.1177/2333721415622004
Spinner DS, Birt J, Walter JW, Bowman L, Mauskopf J, Drummond MF, Copley-Merriman C. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. Clinicoecon Outcomes Res. 2013 Jan 1;5:69-85.
Coffin D, Duval K, Martel S, Granton J, Lefebvre MC, Meads DM, Twiss J, McKenna SP. Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J. 2008 Mar;15(2):77-83.